Sobhy Mohamed, Abdelhamid Magdy, El Etriby Adel Mohamed, Gamaleldin Mohamed Fathy Soliman, Youssef Ahmed Mohamed Helmy, Khalife Natasha, Ragy Hany, Reda Ashraf, Sobhy Maichel, Nawar Mostafa
International Cardiac Center Hospital, 24 Bahaa Eldin Elghatwary St. Semouha, Alexandria, Egypt.
Private Clinic, 09 El Saha St., Bab El Louk, Cairo, 19014, Egypt.
Cardiol Ther. 2025 Jun;14(2):161-182. doi: 10.1007/s40119-025-00400-0. Epub 2025 Mar 21.
Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of newly diagnosed non-valvular atrial fibrillation (NVAF) patients within the MENA region, including Egypt.
This multicenter, prospective, observational registry enrolled newly diagnosed patients with NVAF from January 2020 to December 2022 at eight private-sector healthcare centers in Egypt. Data were collected at enrollment (baseline), and then at 6-month and 12-month follow-up. Baseline data included demographics, AF characteristics, medical history, and antithrombotic treatment patterns. Follow-up data included clinical events, healthcare resource utilization, and related costs.
A total of 723 patients were enrolled. Overall, 51.87% were females, and the mean age was 61.9 years. All patients attended the private health sector. The mean (standard deviation) CHADS-VASc and HAS-BLED risk scores were 2.37 (1.55) and 1.46 (1.18), respectively. Non-vitamin K antagonist oral anticoagulants (62.52%), vitamin K antagonists (22.28%), and antiplatelet therapy (9.85%) were among the prescribed treatments. Rates of transient ischemic attack and all-cause mortality were 2.64% and 0.83%, respectively; all other outcomes (stroke, bleeding, myocardial infarction, systemic embolism) occurred at a rate of ≤ 0.41%. Antithrombotic medications were the major contributors to per-patient total yearly cost (USD 381.2).
The FLOW-AF study showed that patients with NVAF in Egypt are younger and exhibit lower mean baseline CHADS-VASc and HAS-BLED scores compared to Western and other Eastern regions. Additional research, including a broader study population with a longer follow-up, is essential to comprehensively assess the characteristics and outcomes of the NVAF population in Egypt.
包括埃及在内的中东和北非（MENA）地区关于心房颤动（AF）的真实世界数据较为匮乏。FLOW-AF注册研究的目的是评估中东和北非地区（包括埃及）新诊断的非瓣膜性心房颤动（NVAF）患者的特征、治疗模式以及临床和经济结局。
这项多中心、前瞻性观察性注册研究于2020年1月至2022年12月在埃及的8家私立医疗保健中心纳入新诊断的NVAF患者。在入组时（基线）以及6个月和12个月随访时收集数据。基线数据包括人口统计学、房颤特征、病史和抗栓治疗模式。随访数据包括临床事件、医疗资源利用情况及相关费用。
共纳入723例患者。总体而言，51.87%为女性，平均年龄为61.9岁。所有患者均就诊于私立医疗部门。CHADS-VASc和HAS-BLED风险评分的均值（标准差）分别为2.37（1.55）和1.46（1.18）。处方治疗药物包括非维生素K拮抗剂口服抗凝药（62.52%）、维生素K拮抗剂（22.28%）和抗血小板治疗（9.85%）。短暂性脑缺血发作和全因死亡率分别为2.64%和0.83%；所有其他结局（中风、出血、心肌梗死、全身性栓塞）的发生率均≤0.41%。抗栓药物是每位患者每年总费用（381.2美元）的主要构成部分。
FLOW-AF研究表明，与西方和其他东方地区相比，埃及的NVAF患者更年轻，平均基线CHADS-VASc和HAS-BLED评分更低。开展更多研究，包括纳入更广泛的研究人群并进行更长时间的随访，对于全面评估埃及NVAF人群的特征和结局至关重要。
